ACR 2022 Tweet by Robert B Chao, MD

What should you use as a second-line biologic in PsA patients?
In pts who discontinued TNFi, switching to a different MOA led to comparable or better outcomes vs. cycling through another TNFi.
Abs#1600 @RheumNow #ACR22